title: Protective effect of radical scavenger edaravone against puromycin nephrosis.
abstract: OBJECTIVE
  Recent studies have indicated that reactive oxygen species (ROS) play a role in the pathogenesis of glomerular injury leading to proteinuria in nephrotic syndrome. In the present investigation, we examined the effects of the radical scavenger edaravone administered at various time points to rats with puromycin nephrosis.
  
  
  METHODS
  35 Wistar rats were divided into five groups: treatment with puromycin aminonucleoside (PAN) alone, treatment with PAN followed by edaravone in the early period, treatment with PAN followed by edaravone administration in the late period, treatment with PAN and administration of edaravone for the whole experimental period, and untreated controls. On Days 3, 6 and 9, urinary protein excretion was measured. The levels of glomerular thiobarbituric acid-reactive substance (TBArs) were determined in all animals on Day 10.
  
  
  RESULTS
  On Day 9, rats that had been administered edaravone showed reduced urinary protein excretion and reduced glomerular TBArs. In particular, edaravone administration in the late period, during which proteinuria was most acute, had the effect of reducing the severity of proteinuria. Glomerular TBArs were suppressed to the control level. Our results indicate that edaravone exerts a protective effect in the acute phase of PAN nephrosis when administered as antioxidant therapy at the onset of proteinuria.
  
  
  CONCLUSIONS
  Edaravone can ameliorate urinary protein excretion after the onset of proteinuria in nephrotic syndrome.
authors.affiliation: Department of Pediatrics, Osaka Medical College, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Matsumura
authors.forename: A
authors.initials: A
authors.lastname: Ashida
authors.forename: K
authors.initials: K
authors.lastname: Hirano
authors.forename: H
authors.initials: H
authors.lastname: Nakakura
authors.forename: H
authors.initials: H
authors.lastname: Tamai
mesh_terms: D000818:Animals; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004195:Disease Models, Animal; D000077553:Edaravone; D005500:Follow-Up Studies; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D007678:Kidney Glomerulus / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D009401:Nephrosis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D011691:Puromycin / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D016166:Free Radical Scavengers; D017392:Thiobarbituric Acid Reactive Substances; D011691:Puromycin; D000077553:Edaravone; D000983:Antipyrine